Psoriasis

New drug shows results for psoriatic arthritis

harminka — Tue, 07 Apr 2009 12:14:18 -0500

Psoriatic arthritis affects about 11 percent of patients with psoriasis. Anti-tumor necrosis factor α (anti-TNFα) agents, which block signaling molecules that induce inflammation, improve the symptoms of psoriatic arthritis.

New genetic variations linked to psoriasis

harminka — Mon, 26 Jan 2009 10:33:41 -0600

Two international teams of researchers have made significant gains in understanding the genetic basis of psoriasis, a chronic skin condition that can be debilitating in some patients. Their research, involving thousands of patients, is reported in two studies published this week in the advance online Nature Genetics.

Virtual communities may provide valuable support for psoriasis patients

harminka — Tue, 20 Jan 2009 12:51:54 -0600

Online support communities appear to offer both a valuable educational resource and a source of psychological and social support for individuals with psoriasis, according to a report in the January issue of Archives of Dermatology, one of the JAMA/Archives journals.

Regional Factors Add Complexity to Autoimmune Disease Drug Development

mksmith — Thu, 24 Jul 2008 12:05:24 -0500

Applied Data Research Survey Examines Evolving Technology and Strategic Factors

Adalimumab therapy effective in ankylosing spondylitis

harminka — Thu, 12 Jun 2008 09:14:24 -0500

Adalimumab therapy is effective and well-tolerated in ankylosing spondylitis (AS), rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients with a previously inadequate response to anti-tumour necrosis factor (anti-TNF) therapies etanercept and infliximab, according to results of research presented today at EULAR 2008, the Annual European Congress of Rheumatology in Paris, France.

Popular alternative therapy for psoriasis performs no better than placebo

harminka — Sat, 01 Mar 2008 03:26:02 -0600

Anecdotal evidence touting the healing power of the Indian spice turmeric for psoriasis received a setback in a prospective study published this month by a leading dermatology journal stating that the low response rate of patients who ingested the active ingredient of the exotic spice was probably a result of the placebo effect.

Emerging Targets and Therapeutic Approaches Driving Activity in Autoimmune Disease Therapeutics

gstone — Fri, 15 Feb 2008 12:55:00 -0600

New Analysis by Applied Data Research Examines Clinical Developments and Assesses Market Impact

Ustekinumab Phase 3 data show long-term improvement of chronic plaque psoriasis

harminka — Mon, 04 Feb 2008 08:27:08 -0600

One-year data from a second double-blind, placebo-controlled Phase 3 study showed therapy with ustekinumab given every 12 weeks provided sustained, clinically meaningful improvement in the treatment of moderate to severe plaque psoriasis through one year.

Severe psoriasis associated with increased risk of death

harminka — Tue, 18 Dec 2007 12:33:03 -0600

Patients with severe psoriasis appear to have an increased risk of death compared with patients without the skin condition, according to a report in the December issue of Archives of Dermatology, one of the JAMA/Archives journals.

New study shows smoking increases risk of psoriasis

harminka — Mon, 29 Oct 2007 15:29:52 -0500

Another disease can be added to the list of smoking-related disorders -- psoriasis. Researchers have found that smoking increases the risk of developing psoriasis, heavier smoking increases the risk further, and the risk decreases only slowly after quitting.

Ustekinumab significantly improves psoriasis

harminka — Thu, 04 Oct 2007 06:08:59 -0500

The first reported findings from an international, Phase 3 study showed that more than two-thirds of patients with moderate to severe plaque psoriasis receiving two doses of ustekinumab (CNTO 1275) achieved at least a 75 percent reduction in psoriasis at week 12, the primary endpoint of the study, as measured by the Psoriasis Area and Severity Index (PASI 75).

Partnerships Becoming Essential in Autoimmune Therapeutics

gstone — Wed, 05 Sep 2007 09:19:40 -0500

Applied Data Research Finds Regional Factors and Importance of Supplemental Indications Increase the Value of Alliances